Novo Nordisk To Target 'New GLP-1 Patients Only' With Weekly Ozempic

 
• By Sten Stovall
  
Diabetes
Ozempic Is Newest Once-Weekly GLP-1 Agonist To Reach Market For Type 2 Diabetes • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business